Cell Signaling Technology
XP Monoclonal Antibody

Product Pathways - Translational Control

eIF4H (D85F2) XP® Rabbit mAb #3469

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP IF-IC H M R Mk Endogenous 25, 27 Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IF-IC=Immunofluorescence (Immunocytochemistry)
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

eIF4H (D85F2) XP® Rabbit mAb detects endogenous levels of total eIF4H protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the sequence of human eIF4H.

Western Blotting

Western Blotting

Western blot analysis of extracts from HepG2, HeLa and NBT-II cells using eIF4H (D85F2) XP® Rabbit mAb.

IF-IC

IF-IC

Confocal immunofluorescent analysis of HeLa cells (left) and MCF-7 cells (right) using eIF4H (D85F2) XP® Rabbit mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).

Background

A variety of factors contribute to the initiation of translation. Eukaryotic translation initiation factor 4H (eIF4H) was purified to near homogeneity from rabbit reticulocyte lysate and shown to stimulate translation in an assay deficient in eIF4F and eIF4B (1). eIF4H induces the RNA-dependent ATP hydrolysis catalyzed by the initiation factors eIF4A and eIF4B (1,2). eIF4H was further shown to stimulate the initial rate and extent of eIF4A-mediated mRNA secondary structure unwinding (3). Interaction between eIF4H and the herpes simplex virus shutoff protein (Vhs) appears to be important for Vhs-mediated degradation of mRNA (4). Deletion of a large region of chromosome 7, including the corresponding eIF4H gene, results in Williams-Beuren Syndrome (WBS), an autosomal dominant disorder that can present with cardiovascular problems, mental retardation and distinctive facial features (5).

  1. Richter-Cook, N.J. et al. (1998) J Biol Chem 273, 7579-87.
  2. Rogers, G.W. et al. (1999) J Biol Chem 274, 12236-44.
  3. Rogers, G.W. et al. (2001) J Biol Chem 276, 30914-22.
  4. Sarma, N. et al. (2008) J Virol 82, 6600-9.
  5. Osborne, L.R. et al. (1996) Genomics 36, 328-36.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products